Compare ARK Genomic Revolution ETF (ARKG) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Harley-Davidson Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.84, while Harley-Davidson Inc trades at $26 (market cap $2.65B). The key difference: Harley-Davidson Inc pays a 2.92% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Harley-Davidson Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | HOG | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $31.03 |
52-Week Low | $23.09 | $17.19 |
Market Cap | — | $2.65B |
Enterprise Value | — | $3.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Harley-Davidson (HOG) trades at $25.14, up 1.17% today, with a neutral technical outlook and mixed earnings history. The company reported Q1 2026 EPS of $0.22, missing estimates, but Q2 2026 results are due July 23, 2026. Recent news highlights production shifts back to the U.S. and cost-cutting initiatives. Valuation ratios appear attractive with a P/E of 13.03 and P/B of 0.86, though revenue has declined from $5.8B in 2023 to $4.5B in 2025.
The stock faces headwinds from declining revenue and margin pressure, but cost reductions and strategic shifts under new CEO Artie Starrs offer turnaround potential. Analyst consensus is cautious with a $23.20 price target below current levels. Key risks include competitive pressures and execution challenges. The upcoming Q2 earnings will be critical for confirming demand recovery and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
